Page 120 - 《中国药房》2023年21期

[14] MINAMISAWA M，CLAGGETT B，ADAMS D，et al. As‐ [22] CHENG R K，VASBINDER A，LEVY W C，et al. Lack of
sociation of patisiran，an RNA interference therapeutic， association between neurohormonal blockade and survival
with regional left ventricular myocardial strain in heredi‐ in transthyretin cardiac amyloidosis[J]. J Am Heart Assoc，
tary transthyretin amyloidosis：the APOLLO study[J]. 2021，10（24）：e022859.
JAMA Cardiol，2019，4（5）：466-472. [23] SPERRY B W，HANNA M Z，SHAH S J，et al. Spirono‐
[15] FONTANA M，MARTINEZ-NAHARRO A，CHACKO L， lactone in patients with an echocardiographic HFpEF phe‐
et al. Reduction in CMR derived extracellular volume notype suggestive of cardiac amyloidosis：results from
with patisiran indicates cardiac amyloid regression[J]. TOPCAT[J]. JACC Heart Fail，2021，9（11）：795-802.
JACC Cardiovasc Imaging，2021，14（1）：189-199. [24] RUBINOW A，SKINNER M，COHEN A S. Digoxin sensi‐
[16] HABTEMARIAM B A，KARSTEN V，ATTARWALA H， tivity in amyloid cardiomyopathy[J]. Circulation，1981，63
et al. Single-dose pharmacokinetics and pharmacodyna- （6）：1285-1288.
mics of transthyretin targeting N-acetylgalactosamine- [25] GIANCATERINO S，UREY M A，DARDEN D，et al.
small interfering ribonucleic acid conjugate，vutrisiran，in Management of arrhythmias in cardiac amyloidosis[J].
healthy subjects[J]. Clin Pharmacol Ther，2021，109（2）： JACC Clin Electrophysiol，2020，6（4）：351-361.
372-382. [26] EL-AM E A，DISPENZIERI A，MELDUNI R M，et al. Di‐
[17] BENSON M D，WADDINGTON-CRUZ M，BERK J L， rect current cardioversion of atrial arrhythmias in adults
et al. Inotersen treatment for patients with hereditary trans‐ with cardiac amyloidosis[J]. J Am Coll Cardiol，2019，73
thyretin amyloidosis[J]. N Engl J Med，2018，379（1）： （5）：589-597.
22-31. [27] HEIDENREICH P A，BOZKURT B，AGUILAR D，et al.
[18] 田庄，张抒扬.《转甲状腺素蛋白心脏淀粉样变诊断与治 2022 AHA/ACC/HFSA guideline for the management of
疗中国专家共识》解读及诊断路径更新[J]. 罕见病研究， heart failure：executive summary：a report of the American
2023，2（1）：63-69. College of Cardiology/American Heart Association Joint
TIAN Z，ZHANG S Y. The interpretation and update of Committee on clinical practice guidelines[J]. Circulation，
the diagnosis pathway of Chinese expert consensus on the 2022，145（18）：e876-e894.
diagnosis and treatment of transthyretin cardiac amyoido‐ [28] DI LISI D，DI CACCAMO L，DAMERINO G，et al. Ef‐
sis[J]. J Rare Dis，2023，2（1）：63-69. fectiveness and safety of oral anticoagulants in cardiac
[19] GILLMORE J D，DAMY T，FONTANA M，et al. A new amyloidosis：lights and shadows[J]. Curr Probl Cardiol，
staging system for cardiac transthyretin amyloidosis[J]. 2023，48（8）：101188.
Eur Heart J，2018，39（30）：2799-2806. [29] DONNELLY J P，SPERRY B W，GABROVSEK A，et al.
[20] CHENG R K，LEVY W C，VASBINDER A，et al. Digoxin use in cardiac amyloidosis[J]. Am J Cardiol，
Diuretic dose and NYHA functional class are independent 2020，133：134-138.
predictors of mortality in patients with transthyretin car‐ [30] IOANNOU A，PATEL R K，RAZVI Y，et al. Impact of ear‐
diac amyloidosis[J]. JACC CardioOncol，2020，2（3）： lier diagnosis in cardiac ATTR amyloidosis over the
414-424. course of 20 years[J]. Circulation，2022，146（22）：1657-
[21] AIMO A，VERGARO G，CASTIGLIONE V，et al. Safety 1670.
and tolerability of neurohormonal antagonism in cardiac （收稿日期：2023-04-15 修回日期：2023-09-27）
amyloidosis[J]. Eur J Intern Med，2020，80：66-72. （编辑：胡晓霖）

· 2670 · China Pharmacy 2023 Vol. 34 No. 21 中国药房 2023年第34卷第21期